The World Health Organization (WHO) and partners have launched a new global roadmap to tackle hypertensive disorders of pregnancy, including pre-eclampsia, which affect millions of women every year. These disorders remain among the leading causes of death and serious illness for pregnant women and their babies, with tragic long-term impact on their families.
Hypertensive disorders complicate an estimated 10–15% of pregnancies worldwide. They account for around 16% of maternal deaths globally, resulting in an estimated 42 000 deaths each year, as well as more than 500 000 stillbirths and newborn deaths.
In many countries, women still lack reliable access to basic blood-pressure measurement, urine protein testing and essential medicines, including aspirin, antihypertensives and magnesium sulfate. Weak referral systems, shortages of trained health workers and limited emergency obstetric services can further delay life-saving care.
Launched at the Society for Maternal-Fetal Medicine Global Conference, the Global roadmap for hypertensive disorders of pregnancy from 2026 to 2035 and beyond sets out coordinated actions across research and innovation, global clinical guidance, access to medicines and diagnostics, implementation, advocacy and accountability.
The roadmap highlights a striking innovation gap between the scale of the problem and the lack of medicines specifically developed and approved by regulators for the prevention or treatment of pre-eclampsia or eclampsia. Research investment has largely focused on diagnostics, with chronic underinvestment in new preventive and treatment options.
Source: World Health Organization, 8 October 2026
Recommended Comments
Create an account or sign in to comment